U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

Dementia therapies may help relieve symptoms, but many different options are available. Some may help more than others.

The US Food and Drug Administration has approved a new drug to treat schizophrenia after over three decades. As stated in a Sept. 26 press release, the new oral drug, Cobenfy, is a twice-daily pill ...

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...

Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission ...

Scientists have uncovered a mechanism in the brain that explains how drugs like methamphetamine and PCP impair cognitive ...

Aging is an inevitable phenomenon and is accompanied by several comorbidities. To this end, research into the effects of aging has become paramount, and scientists are looking for ways to slow down ...

So Copenhagen University psychologist Vibeke Dam and colleagues took a closer look at the drug's impacts on 90 patients with ...

Researchers have uncovered that SSRIs, specifically escitalopram, not only improve mood in depressed patients but also enhance cognitive functions such as verbal memory. This improvement is linked to ...